Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-0666PMID 18829511
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

  2008cited by this paper
• Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance

  2007cited by this paper
• American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

  2007cited by this paper
• Management of paraproteinaemia

  2007cited by this paper
• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  2007cited by this paper
• Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

  2007cited by this paper
• The effects of intermittent androgen deprivation therapy (ADT) and zoledronic acid administration on bone density in patients with prostate cancer

  2007cited by this paper
• Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

  2007cited by this paper
• Zoledronic acid and clinical fractures and mortality after hip fracture.

  2007cited by this paper
• Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

  2007cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance.

  2006cited by this paper
• Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels.

  2006cited by this paper
• Managing bone complications of solid tumors

  2006cited by this paper
• Fracture risk in patients with monoclonal gammopathy of undetermined significance

  2006cited by this paper
• Monoclonal gammopathy of undetermined significance

  2006cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance.

  2006cited by this paper
• Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance

  2006cited by this paper
• Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.

  2005cited by this paper
• The role of bisphosphonates in breast and prostate cancers.

  2004cited by this paper
• Bisphosphonate Actions on Cancer

  2003cited by this paper
• Fracture Risk in Monoclonal Gammopathy of Undetermined Significance

  2003cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• Antitumor effects of bisphosphonates

  2003cited by this paper
• American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

  2002cited by this paper
• Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

  2002cited by this paper
• Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases

  2001cited by this paper
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  2001cited by this paper
• Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

  2001cited by this paper
• Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen.

  1997cited by this paper
• Transvaginal Sonography of the Endometrium in South Indian Postmenopausal Women

  1997cited by this paper
• THE WORLD HEALTH ORGANIZATION

  1954cited by this paper

• Skeletal health in the precursor stages of multiple myeloma: fracture risk and bone phenotypes in monoclonal gammopathy of undetermined significance and smouldering myeloma.

  2025cites this paper
• Advances in Supportive Care for Multiple Myeloma-Related Bone Disease—A Review

  2025cites this paper
• Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies

  2024cites this paper
• The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies

  2023cites this paper
• Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

  2022cites this paper
• Secondary Osteoporosis.

  2021cites this paper
• Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review

  2021cites this paper
• Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies

  2021cites this paper
• Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.

  2021cites this paper
• Impact of MGUS and myeloma on skeletal health

  2021cites this paper
• Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium.

  2020cites this paper
• Controversies in the use of new bone‐modifying therapies in multiple myeloma

  2020cites this paper
• Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All

  2020cites this paper
• Hematological Diseases and Osteoporosis

  2020cites this paper
• Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

  2020cites this paper
• Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures.

  2019cites this paper
• Understanding and managing secondary osteoporosis

  2019cites this paper
• Medication-Related Osteonecrosis of the Jaws.

  2019cites this paper
• The skeletal impact of cancer therapies.

  2019cites this paper
• Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2018cites this paper
• What is the significance of monoclonal gammopathy of undetermined significance?

  2018cites this paper
• Practical Considerations for Bone Health in Multiple Myeloma

  2018cites this paper
• Bone Disorders in Cancer

  2017cites this paper
• Vitamin D and plasma cell dyscrasias: reviewing the significance

  2017cites this paper
• Personalized Therapy for Multiple Myeloma

  2017cites this paper
• Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

  2017cites this paper
• The effects of weight loss approaches on bone mineral density in adults: a systematic review and meta-analysis of randomized controlled trials

  2016cites this paper
• Handbook of Multiple Myeloma

  2015cites this paper
• Secondary osteoporosis : pathophysiology and management

  2015cites this paper
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

  2015cites this paper
• Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

  2015cites this paper
• Endocrine aspects of bone metastases.

  2014cites this paper
• Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment.

  2014cites this paper
• Medication-Related Osteonecrosis of the Jaw—2014 Update

  2014cites this paper
• Less strength and more fractures for MGUS bones.

  2014cites this paper
• The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

  2014cites this paper
• Secondary Causes of Osteoporosis: Bone Diseases

  2013cites this paper
• Osteoporosis and Cancer

  2013cites this paper
• Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians

  2013cites this paper
• International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

  2013cites this paper
• Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement

  2013cites this paper
• Monoclonal gammopathy of undetermined significance

  2013cites this paper
• Part 7: Monoclonal gammopathy for the non-hematologist oncologist

  2013cites this paper
• Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation

  2013cites this paper
• Découverte d’une gammapathie monoclonale au cours d’une ostéoporose

  2013cites this paper
• Bisphosphonat-assoziierte Kiefer nekrosen

  2012cites this paper
• Clinical trials of bisphosphonates in multiple myeloma.

  2012cites this paper
• Fractal dimension evaluation of cone beam computed tomography in patients with bisphosphonate-associated osteonecrosis.

  2011cites this paper
• A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance.

  2011cites this paper
• Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management

  2011cites this paper
• MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.

  2011cites this paper
• The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

  2011cites this paper
• Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study.

  2011cites this paper
• Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.

  2011cites this paper
• Monoclonal gammopathy of undetermined significance: a consensus statement

  2010influential citation
• Clinical Presentation of Myeloma Bone Disease

  2010cites this paper
• Bisphosphonates in the Treatment of Myeloma Bone Disease

  2010cites this paper
• New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis

  2010cites this paper
• Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

  2010cites this paper
• Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.

  2010cites this paper
• Gammapathie monoclonale de signification indéterminée, myélome multiple et ostéoporose

  2010cites this paper
• The current status and future of multiple myeloma in the clinic.

  2010cites this paper
• Approach to the patient with secondary osteoporosis.

  2010cites this paper
• Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis.

  2010cites this paper
• New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis

  2010cites this paper
• Current World Literature

  2009cites this paper
• Bisphosphonates--what the dentist needs to know: practical considerations.

  2009cites this paper
• Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

  2009cites this paper
• The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).

  2009cites this paper
• Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget’s bone disease

  2009cites this paper
• UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)

  2009cites this paper
• Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference

  2008cites this paper